137 related articles for article (PubMed ID: 36240450)
21. Diffusion-Weighted Imaging in Meningioma: Prediction of Tumor Grade and Association with Histopathological Parameters.
Surov A; Gottschling S; Mawrin C; Prell J; Spielmann RP; Wienke A; Fiedler E
Transl Oncol; 2015 Dec; 8(6):517-23. PubMed ID: 26692534
[TBL] [Abstract][Full Text] [Related]
22. Soft tissue sarcoma: DWI and DCE-MRI parameters correlate with Ki-67 labeling index.
Lee JH; Yoon YC; Seo SW; Choi YL; Kim HS
Eur Radiol; 2020 Feb; 30(2):914-924. PubMed ID: 31630234
[TBL] [Abstract][Full Text] [Related]
23. Role of the Apparent Diffusion Coefficient in the Prediction of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer.
Bufi E; Belli P; Costantini M; Cipriani A; Di Matteo M; Bonatesta A; Franceschini G; Terribile D; Mulé A; Nardone L; Bonomo L
Clin Breast Cancer; 2015 Oct; 15(5):370-80. PubMed ID: 25891905
[TBL] [Abstract][Full Text] [Related]
24. Early prediction of response to neoadjuvant chemotherapy in patients with breast cancer using diffusion-weighted imaging and gray-scale ultrasonography.
Iwasa H; Kubota K; Hamada N; Nogami M; Nishioka A
Oncol Rep; 2014 Apr; 31(4):1555-60. PubMed ID: 24535214
[TBL] [Abstract][Full Text] [Related]
25. Correlation analysis of apparent diffusion coefficient value and P53 and Ki-67 expression in esophageal squamous cell carcinoma.
Wang Y; Bai G; Zhang X; Shan W; Xu L; Chen W
Magn Reson Imaging; 2020 May; 68():183-189. PubMed ID: 31982486
[TBL] [Abstract][Full Text] [Related]
26. Value of pretherapeutic DWI in evaluating prognosis and therapeutic effect in immunocompetent patients with primary central nervous system lymphoma given high-dose methotrexate-based chemotherapy: ADC-based assessment.
Zhang Y; Zhang Q; Wang XX; Deng XF; Zhu YZ
Clin Radiol; 2016 Oct; 71(10):1018-1029. PubMed ID: 27341986
[TBL] [Abstract][Full Text] [Related]
27. Ki-67 labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer.
Jain P; Doval DC; Batra U; Goyal P; Bothra SJ; Agarwal C; Choudhary DK; Yadav A; Koyalla VPB; Sharma M; Dash P; Talwar V
Jpn J Clin Oncol; 2019 Apr; 49(4):329-338. PubMed ID: 30753543
[TBL] [Abstract][Full Text] [Related]
28. Survival impact of postoperative radiotherapy in patients with olfactory neuroblastoma: 513 cases from the SEER database.
Duo GS; Feng JL; Zhang ZY; Wang LJ
Cancer Radiother; 2022 Sep; 26(5):663-669. PubMed ID: 35249817
[TBL] [Abstract][Full Text] [Related]
29. Diffusion-weighted MR imaging in prediction of response to neoadjuvant chemotherapy in patients with breast cancer.
Hu XY; Li Y; Jin GQ; Lai SL; Huang XY; Su DK
Oncotarget; 2017 Oct; 8(45):79642-79649. PubMed ID: 29108344
[TBL] [Abstract][Full Text] [Related]
30. Muscle-invasive bladder cancer: pretreatment prediction of response to neoadjuvant chemotherapy with diffusion-weighted MR imaging.
Zhang X; Wang Y; Zhang J; Xu X; Zhang L; Zhang M; Xie L; Shou J; Chen Y
Abdom Radiol (NY); 2022 Jun; 47(6):2148-2157. PubMed ID: 35306580
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience.
McElroy EA; Buckner JC; Lewis JE
Neurosurgery; 1998 May; 42(5):1023-7; discussion 1027-8. PubMed ID: 9588546
[TBL] [Abstract][Full Text] [Related]
32. Combined dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging to predict neoadjuvant chemotherapy effect in FIGO stage IB2-IIA2 cervical cancers.
Zhang A; Song J; Ma Z; Chen T
Radiol Med; 2020 Dec; 125(12):1233-1242. PubMed ID: 32424659
[TBL] [Abstract][Full Text] [Related]
33. Minimal apparent diffusion coefficient in predicting the Ki-67 proliferation index of pancreatic neuroendocrine tumors.
Xie Y; Zhang S; Liu X; Huang X; Zhou Q; Luo Y; Niu Q; Zhou J
Jpn J Radiol; 2022 Aug; 40(8):823-830. PubMed ID: 35284998
[TBL] [Abstract][Full Text] [Related]
34. Standard diffusion-weighted, diffusion kurtosis and intravoxel incoherent motion MR imaging of sinonasal malignancies: correlations with Ki-67 proliferation status.
Xiao Z; Zhong Y; Tang Z; Qiang J; Qian W; Wang R; Wang J; Wu L; Tang W; Zhang Z
Eur Radiol; 2018 Jul; 28(7):2923-2933. PubMed ID: 29383521
[TBL] [Abstract][Full Text] [Related]
35. Proton beam therapy for olfactory neuroblastoma.
Nakamura N; Zenda S; Tahara M; Okano S; Hayashi R; Hojo H; Hotta K; Kito S; Motegi A; Arahira S; Tachibana H; Akimoto T
Radiother Oncol; 2017 Mar; 122(3):368-372. PubMed ID: 28062086
[TBL] [Abstract][Full Text] [Related]
36. Endoscopic Endonasal Management of Olfactory Neuroblastoma: A Retrospective Analysis of 10 Patients with Quality-of-Life Measures.
Manthuruthil C; Lewis J; McLean C; Batra PS; Barnett SL
World Neurosurg; 2016 Jun; 90():1-5. PubMed ID: 26899467
[TBL] [Abstract][Full Text] [Related]
37. Facial disfigurement due to olfactory neuroblastoma: beauty regained with chemotherapy.
Kumar P; Sundriyal D; Bhandari R; Singh A; Jat B; Sehrawat A
Cancer Rep (Hoboken); 2021 Feb; 4(1):e1303. PubMed ID: 33029949
[TBL] [Abstract][Full Text] [Related]
38. Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer.
Park SH; Moon WK; Cho N; Song IC; Chang JM; Park IA; Han W; Noh DY
Radiology; 2010 Oct; 257(1):56-63. PubMed ID: 20851939
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of
Chodyla M; Demircioglu A; Schaarschmidt BM; Bertram S; Bruckmann NM; Haferkamp J; Li Y; Bauer S; Podleska L; Rischpler C; Forsting M; Herrmann K; Umutlu L; Grueneisen J
J Nucl Med; 2021 Mar; 62(3):348-353. PubMed ID: 32737246
[TBL] [Abstract][Full Text] [Related]
40. Prospective multimodal imaging assessment of locally advanced cervical cancer patients administered by chemoradiation followed by radical surgery-the "PRICE" study 2: role of conventional and DW-MRI.
Gui B; Miccò M; Valentini AL; Cambi F; Pasciuto T; Testa A; Autorino R; Zannoni GF; Rufini V; Gambacorta MA; Giordano A; Scambia G; Manfredi R
Eur Radiol; 2019 Apr; 29(4):2045-2057. PubMed ID: 30324389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
